Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

315 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer.
Matrone A, Prete A, Nervo A, Ragni A, Agate L, Molinaro E, Giani C, Valerio L, Minaldi E, Piovesan A, Elisei R. Matrone A, et al. Among authors: valerio l. J Endocrinol Invest. 2021 Oct;44(10):2139-2151. doi: 10.1007/s40618-020-01491-3. Epub 2021 Feb 17. J Endocrinol Invest. 2021. PMID: 33594641
The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study.
Elisei R, Viola D, Torregrossa L, Giannini R, Romei C, Ugolini C, Molinaro E, Agate L, Biagini A, Lupi C, Valerio L, Materazzi G, Miccoli P, Piaggi P, Pinchera A, Vitti P, Basolo F. Elisei R, et al. Among authors: valerio l. J Clin Endocrinol Metab. 2012 Dec;97(12):4390-8. doi: 10.1210/jc.2012-1775. Epub 2012 Oct 12. J Clin Endocrinol Metab. 2012. PMID: 23066120
Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: clinical implications derived from the first prospective randomized controlled single institution study.
Viola D, Materazzi G, Valerio L, Molinaro E, Agate L, Faviana P, Seccia V, Sensi E, Romei C, Piaggi P, Torregrossa L, Sellari-Franceschini S, Basolo F, Vitti P, Elisei R, Miccoli P. Viola D, et al. Among authors: valerio l. J Clin Endocrinol Metab. 2015 Apr;100(4):1316-24. doi: 10.1210/jc.2014-3825. Epub 2015 Jan 15. J Clin Endocrinol Metab. 2015. PMID: 25590215 Clinical Trial.
Treatment of advanced thyroid cancer with targeted therapies: ten years of experience.
Viola D, Valerio L, Molinaro E, Agate L, Bottici V, Biagini A, Lorusso L, Cappagli V, Pieruzzi L, Giani C, Sabini E, Passannati P, Puleo L, Matrone A, Pontillo-Contillo B, Battaglia V, Mazzeo S, Vitti P, Elisei R. Viola D, et al. Among authors: valerio l. Endocr Relat Cancer. 2016 Apr;23(4):R185-205. doi: 10.1530/ERC-15-0555. Endocr Relat Cancer. 2016. PMID: 27207700 Review.
New insights in the molecular signature of advanced medullary thyroid cancer: evidence of a bad outcome of cases with double RET mutations.
Romei C, Casella F, Tacito A, Bottici V, Valerio L, Viola D, Cappagli V, Matrone A, Ciampi R, Piaggi P, Ugolini C, Torregrossa L, Basolo F, Materazzi G, Vitti P, Elisei R. Romei C, et al. Among authors: valerio l. J Med Genet. 2016 Nov;53(11):729-734. doi: 10.1136/jmedgenet-2016-103833. Epub 2016 Jul 28. J Med Genet. 2016. PMID: 27468888
Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer.
Lorusso L, Pieruzzi L, Biagini A, Sabini E, Valerio L, Giani C, Passannanti P, Pontillo-Contillo B, Battaglia V, Mazzeo S, Molinaro E, Elisei R. Lorusso L, et al. Among authors: valerio l. Onco Targets Ther. 2016 Oct 20;9:6467-6477. doi: 10.2147/OTT.S84625. eCollection 2016. Onco Targets Ther. 2016. PMID: 27799794 Free PMC article. Review.
Targeted Therapy in Thyroid Cancer: State of the Art.
Valerio L, Pieruzzi L, Giani C, Agate L, Bottici V, Lorusso L, Cappagli V, Puleo L, Matrone A, Viola D, Romei C, Ciampi R, Molinaro E, Elisei R. Valerio L, et al. Clin Oncol (R Coll Radiol). 2017 May;29(5):316-324. doi: 10.1016/j.clon.2017.02.009. Epub 2017 Mar 17. Clin Oncol (R Coll Radiol). 2017. PMID: 28318881 Review.
Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life.
Matrone A, Valerio L, Pieruzzi L, Giani C, Cappagli V, Lorusso L, Agate L, Puleo L, Viola D, Bottici V, Del Re M, Molinaro E, Danesi R, Elisei R. Matrone A, et al. Among authors: valerio l. Best Pract Res Clin Endocrinol Metab. 2017 Jun;31(3):319-334. doi: 10.1016/j.beem.2017.06.001. Epub 2017 Jun 15. Best Pract Res Clin Endocrinol Metab. 2017. PMID: 28911728 Review.
315 results